Chronic Immune Thrombocytopenia (ITP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Chronic Immune Thrombocytopenia (ITP) Market Outlook

Thelansis’s “Chronic Immune Thrombocytopenia (ITP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Immune Thrombocytopenia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Immune Thrombocytopenia Overview

Chronic immune thrombocytopenia (ITP) is an autoimmune disease characterized by persistent low platelet counts, which leads to a high risk of uncontrolled bleeding. More severe symptoms include serious bleeding-related episodes (BREs), such as gastrointestinal bleeding, intracranial hemorrhage (ICH) and intra- or post-operative hemorrhage, which are associated with morbidity, mortality and diminished HRQoL. High mortality of Chronic immune thrombocytopenia (ITP) patients reason include severe BREs, infection, cardiovascular disease and hematologic cancer. The risk of ICH in ITP patients has been estimated at 1.5% for adults and 0.5% for children, and the risk of severe (non-ICH) bleeding is estimated at 3–20% in children and approximately 10% in adults. The risk of fatal hemorrhage has been estimated at 0.4% per year in patients 60 years.

• In the United States, the incidence of ITP in adults varies between 16 and 39 cases per million adults per year, with ~4200 to 9750 adults diagnosed with ITP in the USA each year.
• ITP occurs more frequently later in life and rarely resolves without treatment; diagnosis is between 55 and 60 years.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: